Abstract

<div>Abstract<p>Myeloid-derived suppressor cells (MDSC) play a major role in cancer-related immune suppression, yet the nature of this suppression remains controversial. In this study, we evaluated the ability of MDSCs to elicit CD4<sup>+</sup> T-cell tolerance in different mouse tumor models. In contrast to CD8<sup>+</sup> T-cell tolerance, which could be induced by MDSCs in all the tumor models tested, CD4<sup>+</sup> T-cell tolerance could be elicited in only one of the models (MC38) in which a substantial level of MHC class II was expressed on MDSCs compared with control myeloid cells. Mechanistic investigations revealed that MDSCs deficient in MHC class II could induce tolerance to CD8<sup>+</sup> T cells but not to CD4<sup>+</sup> T cells. Unexpectedly, antigen-specific CD4<sup>+</sup> T cells (but not CD8<sup>+</sup> T cells) could dramatically enhance the immune suppressive activity of MDSCs by converting them into powerful nonspecific suppressor cells. This striking effect was mediated by direct cell–cell contact through cross-linking of MHC class II on MDSCs. We also implicated an Ets-1 transcription factor–regulated increase in expression of Cox-2 and prostaglandin E2 in MDSCs in mediating this effect. Together, our findings suggest that activated CD4<sup>+</sup> T cells that are antigen specific may enhance the immune suppressive activity of MDSCs, a mechanism that might serve normally as a negative feedback loop to control immune responses that becomes dysregulated in cancer. <i>Cancer Res; 72(4); 928–38. ©2012 AACR</i>.</p></div>

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call